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“Não sei o que nos espera mas sei o que me preocupa: é que a medicina, empolgada pela 
ciência, seduzida pela tecnologia e atordoada pela burocracia, apague a sua face 
humana e ignore a individualidade única de cada pessoa que sofre, pois embora se 
inventem cada vez mais modos de tratar, não se descobriu ainda a forma de aliviar o 
sofrimento sem empatia ou compaixão.” 
 
João Lobo Antunes 
in "A Nova Medicina" 
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Abstract 
Background The association between human papillomavirus (HPV) and Non-Melanoma 
Skin Cancer (NMSC) remains undefined, with studies showing controversial results. 
Objective We aim to determine if there is a significant association of HPV with 
Cutaneous Squamous Cell Carcinoma (cuSCC) and Basal Cell Carcinoma (BCC) and 
whether the prevalence of HPV is higher in those tumors from immunosuppressed 
patients when compared with tumors from immunocompetent patients. 
Methods We conducted a systematic review and meta-analysis of observational studies. 
We searched four electronic databases up to March 2017, reviewed references of 
relevant articles and hand searched conference proceedings. The following search terms 
were used: skin cancer, squamous cell skin carcinoma, basal cell skin carcinoma and 
human papillomavirus. Only studies including biopsy samples evaluated by a 
pathologist, HPV detection by polymerase chain reaction (PCR) and a minimum of 10 
cases and 10 controls were considered. Pooled effect size and 95% confidence intervals 
were calculated using random effects meta-analysis and the inverse variance method. 
Results Of 2740 articles identified, 23 met the eligibility criteria. cuSCC were more likely 
to carry HPV than normal-appearing skin - pooled odds ratio (OR) 3.29 (95% CI 1.67-
6.46). The overall association between HPV and BCC was also significant - pooled OR 
2.56 (95% CI 1.48-5.14). An increase in HPV prevalence was found in cuSCC tumors from 
immunosuppressed patients when compared with immunocompetent patients - pooled 
OR 3.07 (95% CI 2.08-4.52). The same prevalence was not significant in BCC - pooled OR 
2.38 (95% CI 0.95-5.96). 
Conclusion These results support those studies that reported an association between 
HPV and NMSC, particularly in cuSCC and in tumors from immunosuppressed patients. 
Such evidence may have future research and clinical implications. 
 
Keywords human papillomavirus; squamous skin cell carcinoma; basal skin cell 
carcinoma; meta-analysis; immunosuppression; systematic review.   
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Introduction 
Non-Melanoma Skin Cancer (NMSC) comprises Basal Cell Carcinoma (BCC) and 
Cutaneous Squamous Cell Carcinoma (cuSCC) as the major representatives.1 BCC is the 
most common skin cancer2 and is the most prevalent cancer in many countries 
worldwide.3 On the other hand, cuSCC is the second most frequent form of skin cancer.4 
Reports from the World Health Organization estimate an occurrence of 2 to 3 million 
cases of NMSC annually worldwide.5 The annual cost of treating skin cancers is 
estimated at $8.1 billion, $4.8 billion for NMSC in the United States.6 NMSC is also a 
significant economic burden in European health expenditure, with €5.2 million annually 
costs for inpatient care attributable to these cancers in Sweden7 and €105 to €130 
million estimated annually costs of hospitalization in Germany.8  
Ultraviolet Radiation (UVR) exposure is the main recognized risk factor for NMSC. 
About 90 percent of NMSC are associated with exposure to UVR from the sun9, but other 
risk factors have been studied as fair skin, older age and immunosuppression.10 For 
instance, organ transplanted patients are approximately 100 times more likely to 
develop cuSCC than general population.11 Considering the increased prevalence and the 
clinical behavior of NMSC and the high incidence of virally induced neoplasia such as 
Kaposi Sarcoma (Human Herpesvirus 8) in this cluster of patients, a viral etiology has 
also been hypothesized12, 13 associated with NMSC. 
More than 170 types of small capsid-enclosed double-stranded DNA human 
papillomaviruses (HPV) have been described.14Taxonomy recognizes five main HPV 
genera: alfa-, beta-, gamma-, mu- and nu- viruses.15 Their oncogenic potential has been 
studied both in vitro and in vivo models demonstrating a well-established role of alfa-
HPV in cervical carcinoma in an important portion of other anogenital, head and neck 
and oropharyngeal malignancies.16  
In the last decades, the biology and contribution of HPV to NMSC development 
in previously healthy skin has been studied but controversial results were found and 
different methodological approaches were used.  
Public health interventions have been launched to minimize the burden of HPV-
associated malignancies, including worldwide vaccination programs against the most 
oncogenic viruses.16 A better understanding of the relation between HPV and NMSC 
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would help to develop more effective preventive measures (such as vaccination) 
decreasing, therefore, the number of newly diagnosed cases 
and consequently the financial burden. 
The main aim of the present study was to perform a systematic review and meta-
analysis to determine the association of HPV with cuSCC and BCC. We also sought to 
ascertain whether the prevalence of HPV is higher in those tumors from 
immunosuppressed patients when compared with NMSC from immunocompetent 
patients. 
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Material and methods 
 A systematic review and meta-analysis of observational studies focusing on the 
association between NMSC and the presence of human papillomaviruses in skin was 
performed. The methodology included definition of selection criteria and search 
strategy, quality assessment, data abstraction, bias risk assessment and statistical 
analysis. PRISMA statement was followed.17 
Selection criteria 
 The study eligibility criteria were determined before data collection in order to 
properly identify high quality studies appropriate for the analysis. 
The following eligibility criteria were defined. Patient population: 
immunocompetent or immunosuppressed patients presenting healthy normal skin 
(controls) or non-anogenital NMSC lesions including Keratoacanthoma (KA), in situ 
cuSCC, invasive cuSCC or BCC (cases) reported by a pathologist, without other cutaneous 
comorbid conditions (Epidermolysis Verruciformis or other genodermatosis). Study 
design: observational studies with a minimum of 10 cases and 10 controls or a minimum 
of 20 patients. Exposure: HPV presence in skin detected by polymerase chain reaction-
based (PCR) methods in biopsy samples. Outcome: NMSC occurrence in both 
immunocompetent and immunosuppressed subpopulations (Table 1). INSERT T1 
Search strategy 
Our primary method to identify potentially eligible studies was an electronic 
biomedical literature search in the MEDLINE database, considering articles published 
until to March 10, 2017, written in English, using the following search keywords (skin 
cancer or squamous cell skin carcinoma or basal cell skin carcinoma) and human 
papillomavirus and MeSH terms: “skin neoplasms”, “carcinoma, squamous cell”, 
“carcinoma, basal cell” and “papillomaviridae”. Literature search was also performed, 
using the previous search keywords, in other three major databases: the Cochrane 
Library; the SciVerse Scopus; and the Web of Science. 
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We also reviewed the references list of all pertinent articles to recognize 
potentially appropriate studies. Abstracts from relevant conferences and scientific 
forums were also searched. 
Duplicated articles were excluded and all the articles were uploaded to 
Covidence systematic review manager for quality assessment and further selection. 
Quality assessment and data abstraction 
During the first phase of selection, each article was independently reviewed by 
two of the authors, based on its title and abstract to screen for relevance.  
In the second phase, articles were independently full-text scrutinized by two 
reviewers, De-Pinho A.A. and Lisboa C. Selection criteria were applied, exclusions were 
decided and disagreements settled by consensus. 
A standard data abstraction form was created by De-Pinho A.A. and Santos J.V. 
Each article was checked independently and all relevant data was extracted 
independently and in duplicate for each article by De-Pinho A.A. and Ramalho A.L.C. Any 
discrepancies in the duplicates were solved by the authors by discussing and achieving 
consensus. 
General data extracted from each study included authors’ names, year of 
publication, general study design, studied malignancies, tumour body locations, HPV 
subtypes that were searched, total numbers or HPV positive/HPV negative samples of 
cuSCC, BCC, normal skin, cuSCC or BCC in immunosuppressed or immunocompetent 
patients, depending on the hypothesis tested as well as other relevant information 
concerning methodological specificities to facilitate the assessment of bias risk. Extra 
data relative to age, sex, race, skin type, sun exposure, immunosuppression and PCR 
methodology details were also collected when available (Table 2). INSERT T2 
Following the Newcastle-Ottawa Scale (NOS), the risk of bias in all reviewed 
studies was assessed regardless of the anticipated variability in outcomes or the validity 
of the included studies. Two reviewers performed the NOS assessment individually. 
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Evaluations were performed according to manual coding for observational 
studies, covering the domains: selection, comparability and exposure. Dispute 
resolutions between the two reviewers were conducted by consensus method.    
Statistical methods 
For the assessment of the effect of HPV in the development of cuSCC or BCC, as 
well in the immunosuppression of both, we used the generic inverse variance method 
for both fixed and random effects estimation. 
Generic inverse variance was used as data type for measuring the HPV effect in 
the outcomes as it is the optimal measure to describe retrospective exposure effects. 
Odds ratio (ORs) with the corresponding 95% confidence intervals (CI) were abstracted 
from each article. We identified the ORs reflecting the greatest degree of adjustment 
for possible confounding factors. When adjusted values were absent, we collected crude 
values. As a last resort, if ORs were not mentioned in the selected study, we calculated 
them based on the number of cases and controls described in the study. Random-effects 
method was used to pool the ORs and 95% CIs. 
 Heterogeneity of exposure effect was assessed by graphical inspection of forest 
plots and formally using the Q statistic (at a p value <= 0.1) and I2 statistic for studying 
studies’ consistency.  
 Potential publication bias was assessed by visual analysis of funnel plots and 
analysis using Begg test.  
 Data processing and statistical analysis were performed using Review Manager 
(RevMan) software version 5.3.  
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Results 
Search and study selection 
The literature search protocol described above yielded a total of 2740 studies. 
During this process, two previous meta-analysis on the subject were identified – Wang 
et al18 and Chahoud et al19 and articles included in those studies were selected for our 
screening. No abstracts from relevant conferences and scientific forums were found. 
After review of the titles and abstracts, a total of 2577 were excluded for non-
compliance with the eligibility criteria. De-Pinho A.A. and Lisboa C. reviewed the full text 
of the remaining 163 articles. Selection criteria were applied, exclusions were decided 
and disagreements settled by consensus. After the final screening, 23 studies were 
selected (Fig. 1). INSERT F1 
Study characteristics 
All the 23 included studies in our meta-analysis were case-controls (no cohort 
studies were identified). Depending on the outcome, a different number of studies was 
considered for statistical analysis (Fig. 1; Table 2). Some studies were included in more 
than one hypothesis analysis as they addressed more than one outcome.  
Publication years ranged from 1996 to 2014. All studies included both male and 
female patients ranging all ages and resulted in a total of 558 cases and 907 controls for 
hypothesis A, 370 cases and 667 controls for hypothesis B, 444 cases and 286 controls 
for hypothesis C and 72 cases and 42 controls for hypothesis D. 
After data collection, we recognized that, depending on the study, “cuSCC 
samples” included invasive cuSCC and/or in situ cuSCC and/or Keratoacanthoma. 
“Normal skin” was a reference to normal skin tissue from patients with cuSCC/BCC or 
normal skin samples from paired controls without tumours, depending on the studies, 
but always reported by a pathologist. Benign lesions were not included. 
Some studies included in this meta-analysis evaluated several body locations, 
namely anogenital lesions.20 Since those cases did not meet our eligibility criteria, they 
were excluded. This may explain a discrepancy between the values present in our meta-
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analysis and the ones described in the original study. Samples that did not described the 
specific body location of the lesion or mentioned it only as “unknown” were included.  
All the selected studies used PCR-based methods to identify the HPV presence in 
skin biopsies, but the genera/subtype detected was different among the case-controls, 
varying from broad spectrum, including alpha, beta and even gamma genera to only a 
specific HPV subtype.21 
Only two of the selected studies presented adjusted OR: Forslund et al22 – 
adjustment for age, sex, skin type, self-reported previous sunburns, eye colour and sun 
exposure; and Iftner et al23 – adjustment for age, sex and sun exposure. 
Additional information and abstracted data from the included studies are 
presented in Table 2. 
Methodological quality of included studies 
Quality assessment was performed using the NOS, covering the following 
domains: selection, comparability and exposure. Scores ranged from 5 to 9 (9 being the 
highest possible score), with a mean of 8.3 and median of 9 (Table 3). 
Despite the presence of some possible bias in five studies23,24,25 ,26,27 which scored 
7 or less, they were relevant enough to be included.  INSERT T3 
Publication bias  
Considering the existence of approximately symmetrical funnel plots among the 
studied hypothesis B, C and D, selected studies from these hypotheses seemed to show 
no evidence of publication bias. On the other hand, the funnel plot regarding hypothesis 
A showed some grade of asymmetry. For a better understanding, Begg test was applied 
to the four funnel plots and detected no evidence of publication bias among the four 
studied hypothesis (Fig. 2). INSERT F2 
Meta-analysis 
Hypothesis A - HPV association with cuSCC versus normal skin 
A total of 11 studies comprising 558 cases and 907 controls were considered. In 
this pooled analysis, overall HPV-cuSCC association was significant with pooled OR 3.29 
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(CI 95%, 1.67-6.46, p < 0.001), showing that squamous cell carcinomas were more likely 
to carry HPV than normal-appearing skin. I2 and Q statistics showed significant level of 
heterogeneity in the published studies, suggesting that individual study effect sizes 
varied based on different study designs, I2 = 77.0%, Q = 43.94, p < 0.001 (Fig. 3). INSERT 
F3 
Hypothesis B - HPV association with BCC versus normal skin 
Seven studies met the eligibility criteria, resulting in a total of 370 cases and 667 
controls. In our random effects pooled analysis, BCC was more likely to carry HPV than 
normal skin (pooled OR 2.56, CI 95%, 1.48-5.14, p = 0.008). I2 and Q statistics showed 
moderate evidence of heterogeneity in the published studies, I2 = 62.0%, Q = 15.82, p = 
0.01 (Fig. 4). Removing studies one by one, we found that the exclusion of Caldeira et 
al21, considerable changed the level of heterogeneity. In the absence of this article, the 
pooled effect was OR 1.86, CI 95%, 1.10–3.14 and I2 = 25.0%, p = 0.25. INSERT F4 
Hypothesis C - HPV association with cuSCC in immunosuppressed versus 
immunocompetent patients 
In this pooled analysis, 444 cases and 286 controls from 12 case-controls were 
included. cuSCC from immunosuppressed patients was significantly more likely to carry 
HPV than cuSCC samples from non-immunosuppressed patients (pooled OR 3.07, CI 
95%, 2.08-4.52, p < 0.001). I2 and Q values showed no significant level of heterogeneity 
in the published studies, I2 = 22.0%, Q = 14.07, p = 0.23 (Fig. 5). INSERT F5 
Hypothesis D - HPV association with BCC in immunosuppressed versus 
immunocompetent patients 
Only 3 studies (72 cases and 42 controls) were included. The random effects 
pooled analysis on this outcome showed a non-statistically significant difference 
between immunosuppression and HPV presence in BCC (pooled OR 2.38, CI 95%, 0.95-
5.96, p = 0.07). I2 and Q statistics showed no significant level of heterogeneity in the 
published studies, I2 = 0%, Q = 0.06, p = 0.97 (Fig. 6). INSERT F6 
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Discussion 
 
In our analysis studied populations varied from 23 samples (11 cases and 12 
controls) to 540 samples (148 cases and 392 controls) with more than half of the studies 
including over 50 samples. About half of the selected case-controls were relatively 
recent (within the last 10 years). In general, the newer studies included broad-spectrum 
PCR techniques being able to detect more HPV types, specially beta-genera. Detected 
HPV varied from one specific HPV subtype to broad spectrum mucosal and cutaneous 
HPV, covering various genera.  
Concerning cuSCC, these tumors were more likely to carry HPV than normal-
appearing skin and immunosuppressed patients were more likely to carry HPV than 
immunocompetent patients. Therefore, our analysis shares similar results with the two 
previous identified meta-analysis on the subject.18,19 However, Chahoud et al19 did not 
included an analysis in immunosuppressed patients which represent a significant 
portion of the patients with cuSCC and allowed a wider range of methodologies to detect 
HPV, including multiplex and ELISA serologies.  
Interestingly, HPV load seems to decrease during cuSCC carcinogenesis. Some 
studies refer a higher prevalence of HPV DNA in Actinic Keratosis (AK), a cuSCC 
premalignant lesion, comparing with the subsequent rates detected in cuSCC.28 Another 
curious issue is that skin cells, unlike cells studied in the cervical region, do not require 
the expression of oncoproteins (like E6 and E7) by HPV viruses to preserve their 
transformed phenotype.28 Finally, studies have failed to detect messenger RNA from 
beta-genus in cuSCC samples.29 These three previous facts may suggest a temporary 
early role of HPV in the multistep process of oncogenesis and no need of these viruses 
for maintenance. We can speculate if HPV works as co-carcinogen factor with UVR. 
Actually, some studies have identified higher HPV rates in sun-exposed regions.22 A local 
immunosuppression effect of UVR30 or a direct trigger effect in viruses may induce 
apoptosis or DNA damage. This last theory was already demonstrated in vitro with 
cutaneous HPV types 5, 8, 20 and 77.31,32 
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There might also be different mechanisms driving tumor progression in HPV DNA 
positive versus HPV DNA negative cuSCC. Apart from the importance of studying the 
natural history of the carcinogenesis in HPV DNA positive cuSCC, immunological and 
genetic factors that are associated with HPV DNA negative tumors should also be better 
explored in the future. 
Regarding BCC, no previous meta-analysis were found and the association with 
HPV was demonstrated for the first time in literature. Even without a statistically 
significance, BCC from immunosuppressed patients were more likely to carry HPV than 
tumors from immunocompetent patients.  
Studies involving BCC tumours were, in general, more recent 21-23, 25, 33-38 and a 
lack in both quantity and quality of case-controls on BCC, particularly involving 
immunosuppressed patients (low number of cases and controls for hypothesis D) was 
found. This fact may be due to an easier logical reasoning relating cuSCC with HPV 
(rather than BCC), as the causality of papillomaviruses and carcinoma of the cervix in 
women (affecting squamous cells) is well-established.  Additionally, in contrast to the 
immunocompetent population, cuSCC is more common in immunosuppression context 
than BCC.39 New studies, covering a larger number of patients with BCC and 
preferentially prospective designed, would improve the quality of future meta-analysis 
in this matter. 
The role of HPV in cutaneous carcinogenesis is far away from being completely 
understood. Even though our results demonstrate a strong association between HPV 
and NMSC, a higher prevalence of the virus in tumoral tissues does not imply causality. 
It is from great importance to differentiate if the HPV infection is only a simultaneously 
phenomenon with the occurrence of neoplasia or a major agent during the process of 
carcinogenesis.40 Thus, cohort studies should be designed and performed to assess this 
causality, adjusting for other risk factors. 
Definition of a causality link between NMSC and HPV may lead to new diagnostic 
and therapeutic tools. For instance, the well-established relationship between cervical 
carcinoma and HPV provided effective HPV vaccines and a better control of this cancer.16 
Acquired immunity through vaccination against selected HPV subtypes could potentially 
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be explored as an effective preventive approach, decreasing NMSC burden and further 
costs of care. 
This meta-analysis has some limitations that should be pointed out.  
Unfortunately, most of the studies did not present adjusted measures for 
possible confounding factors, particularly for exposure to UVR and older age, known 
NMSC risk factors. 
Other important limitation is the great degree of heterogeneity among the 
literature regarding sampling methods, the laboratory technique to HPV detection and 
the HPV type studied. We specifically tried to minimize these points, considering only 
studies based on biopsy samples evaluated by experienced pathologists or PCR 
techniques for HPV detection rather than eyebrow pluck, skin swab or serologies.  
Conclusions 
  This study represents, to our knowledge, the most extensive meta-analysis 
assessing the epidemiological association of HPV with cuSCC using PCR analysis. 
Notably, this is the first meta-analysis evaluating the association between HPV 
and BCC. This work provides additional evidence of the eventual involvement of HPV in 
the development of these tumors in both immunocompetent and immunosuppressed 
individuals.  
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Tables 
Table 1  
 
Eligibility Criteria 
Article in English, excluding abstracts, reviews and letters to the editor 
Minimum of 10 cases and 10 controls/20 patients for determination of Odds Ratio (OR) 
Patients without other cutaneous comorbid conditions (Epidermodysplasia Verruciformis or other genodermatosis) 
Samples including all skin body areas except anogenital  
Biopsy samples only (rather than eyebrow pluck, skin swab or serology) 
HPV detection by PCR-based methods 
Outcome (at least one): 
- For hypothesis A – HPV-PCR positivity in cuSCC versus normal skin 
- For hypothesis B – HPV-PCR positivity in BCC versus normal skin 
- For hypothesis C – HPV-PCR positivity in cuSCC from immunosuppressed patients versus cuSCC from immunocompetent patients 
- For hypothesis D – HPV-PCR positivity in BCC from immunosuppressed patients versus BCC from immunocompetent patients 
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Table 2  
 
Source 
Design and 
population 
(hypothesis) 
HPV subtypes Malignancies  Tumor Body Locations 
Arends et al,41 1997 Case-control 
27 cases 15 controls – C 
HPV subtypes 1, 2, 5, 8, 6b, 11, 16 
and 18  
cuSCC  Sun-exposed and non-sun-exposed areas 
Arron et al,29 2011 Case-control 
67 cases 18 controls – A 
39 cases 28 controls – C 
Broad spectrum beta-HPV 
cuSCC, KA type 
included  
 Sun-exposed and non-sun-exposed areas 
Asgari et al,24 2008 Case-control 
85 cases 190 controls - A 
Broad spectrum HPV (including 
alpha, beta and gamma genera) 
cuSCC Sun-exposed and non-sun-exposed areas 
Berkhout et al33, 2000 Case-control 
81 cases 31 controls – A 
14 cases 31 controls – B 
Broad spectrum HPV (including 
alpha and beta genera) 
cuSCC and BCC Sun-exposed and non-sun-exposed areas 
Bernat-García et al,25 
2014 
Case-control 
17 cases 17 controls – C 
13 cases 13 controls – D 
Broad spectrum HPV (including 
alpha, beta and gamma genera) 
cuSCC and BCC  Sun-exposed and non-sun-exposed areas 
Cairey-Remonnay et al,42 
2002 
Case-control 
53 cases 51 controls - C 
Broad spectrum of mucosal and 
cutaneous HPV 
cuSCC  Sun-exposed areas 
Caldeira et al,21 2003 Case-control 
26 cases 41 controls – A 
69 cases 41 controls – B 
HPV subtype 38 cuSCC and BCC  ND 
Escutia et al,34 2011 Case-control 
70 cases 29 controls - B 
Broad spectrum HPV (including 
alpha, beta and gamma genera) 
BCC  Sun-exposed and non-sun-exposed areas 
Forslund et al,43 003 Case-control 
11 cases 12 controls - C 
Broad spectrum of cutaneous HPV cuSCC  Sun-exposed and non-sun-exposed areas 
Forslund et al,44 2003,  
2nd article 
Case-control 
60 cases 12 controls - C 
Broad spectrum of cutaneous HPV cuSCC, only KA ND 
Forslund et al,22 2007 Case-control 
82 cases 392 controls- A 
148 cases 392 controls – B 
Broad spectrum HPV (including 
alpha, beta and gamma genera) 
cuSCC and BCC  Sun-exposed and non-sun-exposed areas 
Gustafsson et al,45 2004 Case-control 
36 cases 27 controls - A 
Broad anogenital HPV cuSCC  ND 
Hama et al,20 2006 Case-control 
23 cases 17 controls- A 
Broad spectrum of mucosal HPV cuSCC  Sun-exposed and non-sun-exposed areas 
Harwood et al,35 2000 Case-control 
44 cases 22 controls – C 
24 cases 11 controls – D 
Broad spectrum of cutaneous, 
mucosal and EV HPV  
cuSCC and BCC  Sun-exposed and non-sun-exposed areas 
Iftner et al,23 2003 Case-control 
72 cases 106 controls – A 
18 cases 106 controls – B 
Broad spectrum of mucosal and EV 
HPV  
cuSCC and BCC  Sun-exposed and non-sun-exposed areas 
Mackintosh et al,26 2009 Case-control 
53 cases 11 controls – A 
30 cases 23 controls – C 
Broad spectrum beta-HPV  
cuSCC, KA 
included in IS 
group  
ND 
Plasmeijer et al,27 2010 Case-control 
21 cases 21 controls – A 
Broad spectrum beta-HPV  cuSCC  Sun-exposed and non-sun-exposed areas 
Purdie et al,46 2005 Case-control 
84 cases 17 controls - C 
Broad spectrum cutaneous HPV  cuSCC  ND 
Reuschenbach et al,36 
2011 
Case-control 
43 cases 44 controls – C 
35 cases 18 controls – D 
HPV subtypes 16, 18, 31, 33, 
35,39, 45, 51, 52, 56, 58, 59, 68, 
73, and 82 
cuSCC, KA 
included and 
BCC  
Sun-exposed and non-sun-exposed areas 
Rollison et al,37 2008 Case-control 
13 cases 15 controls - B 
Broad spectrum beta-HPV  BCC Sun-exposed and non-sun-exposed areas 
Shamanin et al,47 1996 Case-control 
20 cases 26 controls - C 
Broad spectrum HPV cuSCC ND 
Stockfleth et al,48 2004 Case-control 
16 cases 19 controls - C 
Broad spectrum mucosal, EV and 
classical wart-associated HPV 
cuSCC  ND 
Zaravinos et al,38 2010 Case-control 
12 cases 53 controls – A 
38 cases 53 controls – B 
Broad spectrum HPV cuSCC and BCC  Sun-exposed and non-sun-exposed areas 
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Table 3 
 
Source Newcastle-Ottawa Score OR Adjustment 
Arends et al,41 1997 8 -- 
Arron et al,29 2011 8 -- 
Asgari et al,24 2008 7 -- 
Berkhout et al,33 2000 9 -- 
Bernat-García et al,25 2014 7 -- 
Cairey-Remonnay et al,42 2012 9 -- 
Caldeira et al,21 2003 9 -- 
Escutia et al,34 2010 9 -- 
Forslund et al,43 2003 9 -- 
Forslund et al,44 2003, 2nd article 9 -- 
Forslund et al,22 2007 9 Adjusted for age, sex, skin type, self-
reported previous sunburns, eye color 
and sun exposure at biopsy site 
Gustafson et al,45 2004 9 -- 
Hama et al,20 2006 9 -- 
Harwood et al,35 2000 9 -- 
Iftner et al,23 2003 5 Adjusted for age, sex and sun exposure 
(sun exposed: head, face, neck, 
forearm, hands, and lower limb) 
Mackintosh et al,26 2009 5 -- 
Plasmeijer et al,27 2010 7 -- 
Purdie et al,46 2005 9 -- 
Reuschenbach et al,36 2011 9 -- 
Rollison et al,37 2008 9 -- 
Shamanin et al,47 1996 9 -- 
Stockfleth et al,48 2004 9 -- 
Zaravinos et al,38 2010 9 -- 
 
 
 
 
 
  
22 
Figures 
Fig. 1  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Records identified through database 
searching 
2737 
Additional records identified through 
other sources 
3* 
Records screened  
2740 
Records excluded based on 
title and abstract 
2577 
 
Full-text articles assessed for 
eligibility 
163 
Full-text articles excluded 
that did not met inclusion 
criteria 
140 
 
1) Different setting 70 
 
2) Wrong study design 56 
 
3) Wrong outcomes 14 
 
Studies included in 
quantitative synthesis   
(meta-analysis) 
23 
Hypothesis A 
HPV-PCR positivity in cuSCC 
versus normal skin 
 
11 Studies 
Hypothesis B 
HPV-PCR positivity in BCC 
versus normal skin 
 
7 Studies 
 
Hypothesis C 
HPV-PCR positivity in cuSCC 
from immunosuppressed 
patients versus cuSCC from 
immunocompetent patients 
12 Studies 
 
Hypothesis D  
HPV-PCR positivity in BCC 
from immunosuppressed 
patients versus BCC from 
immunocompetent patients 
3 Studies 
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Legends 
Table 1 – Eligibility criteria for systematic review. 
Table 2 – Characteristics of studies meeting search eligibility criteria.  
IS – Immunosuppressed; KA – Keratoacanthoma; ND – Not defined.  
Table 3 - Newcastle-Ottawa scale for assessment of quality and OR adjustment of the 
included studies. 
 
Fig. 1 - Flow chart of search strategy for the meta-analysis and number of studies 
included in final quantitative analysis by hypothesis. 
* Records included in previous meta-analysis and that were not selected via research 
protocol. 
** Some studies were included in more than one hypothesis analysis as they met criteria 
for both. 
Fig. 2 – Funnel plots with effect measures (Odds Ratio (OR) as a function of its standard 
error (SE)) for the outcome of HPV positivity in studies comparing (a) cuSCC versus 
normal skin – Begg test: p = 0.2183; (b) BCC versus normal skin – Begg test: p = 0.8406; 
(c) cuSCC from immunosuppressed patients versus cuSCC from immunocompetent 
patients – Begg test: p = 0.7726; (d) BCC from immunosuppressed patients versus BCC 
from immunocompetent patients – Begg test: p = 1.0000. 
Fig. 3 – Forest plot with pooled effect size and 95% confidence intervals (CI) for 
hypothesis A - HPV-PCR positivity in cuSCC versus normal skin. The squares and 
horizontal lines correspond to the study-specific odds ratios (ORs) and 95% CIs. The 
diamond shape represents the pooled OR and 95% CI of the overall population. 
Fig. 4 – Forest plot with pooled effect size and 95% confidence intervals (CI) for 
hypothesis B - HPV-PCR positivity in BCC versus normal skin. The squares and horizontal 
lines correspond to the study-specific odds ratios (ORs) and 95% CIs. The diamond shape 
represents the pooled OR and 95% CI of the overall population. 
29 
Fig. 5 – Forest plot with pooled effect size and 95% confidence intervals (CI) for 
hypothesis C - HPV-PCR positivity in cuSCC from immunosuppressed patients versus 
cuSCC from immunocompetent patients. The squares and horizontal lines correspond 
to the study-specific odds ratios (ORs) and 95% CIs. The diamond shape represents the 
pooled OR and 95% CI of the overall population. 
Fig. 6 – Forest plot with pooled effect size and 95% confidence intervals (CI) for 
hypothesis D - HPV-PCR positivity in BCC from immunosuppressed patients versus BCC 
from immunocompetent patients. The squares and horizontal lines correspond to the 
study-specific odds ratios (ORs) and 95% CIs. The diamond shape represents the pooled 
OR and 95% CI of the overall population. 
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